Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adma Biologics
(NQ:
ADMA
)
10.62
+0.18 (+1.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,317,923
Open
10.43
Bid (Size)
10.36 (10)
Ask (Size)
10.58 (1)
Prev. Close
10.44
Today's Range
10.43 - 10.88
52wk Range
3.060 - 10.88
Shares Outstanding
196,357,149
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
June 14, 2024
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.
Via
Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
June 12, 2024
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.
Via
Investor's Business Daily
Performance
YTD
+133.41%
+133.41%
1 Month
+12.86%
+12.86%
3 Month
+71.57%
+71.57%
6 Month
+151.66%
+151.66%
1 Year
+172.31%
+172.31%
More News
Read More
Krystal Biotech Stock Sees RS Rating Jump To 91
June 11, 2024
Via
Investor's Business Daily
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
May 10, 2024
Via
Benzinga
ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results
May 10, 2024
Via
Benzinga
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
March 26, 2024
Via
Benzinga
Forecasting The Future: 4 Analyst Projections For ADMA Biologics
February 29, 2024
Via
Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 10, 2024
Via
Benzinga
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Recap: ADMA Biologics Q4 Earnings
February 28, 2024
Via
Benzinga
Earnings Preview For ADMA Biologics
February 27, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For ADMA Biologics
January 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
May 09, 2024
Via
Benzinga
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
Chart Of The Day: ADMA Biologics - Hitting New Highs
May 06, 2024
Via
Talk Markets
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
March 11, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
March 05, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces CFO Transition
February 28, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 28, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
February 21, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
February 21, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
January 08, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
December 18, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
December 12, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.